Save up -80% on Ulobetasol
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Halobetasol
|$25.08||1 tube (15g) 0.05% cream|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Halobetasol coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Ulobetasol every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Ulobetasol volume of distribution
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ulobetasol
Ulobetasol (as ulobetasol propionate) is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Ulobetasol mechanism of action
Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.
Dosage forms of Ulobetasol
21-chloro diflorasone Halobetasol
E. Fougera CO., A division of Fougera Pharmaceuticals Inc.
Humans and other mammals
Indication of Ulobetasol
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Toxicity of Ulobetasol
The acute oral (LD50) toxicity of halobetasol propionate was determined in beagle dogs. Halobetasol propionate was administered via gelatin capsules at an oral dose level of 3000 mg/kg to a study group of 1/sex. Emesis occurred in the male after dosing. General toxicity signs were an initial marked but a reversible decrease in eosinophils, with decreased cortisol values observed during the 2 week study. There were no deaths. The acute oral (LD50) of halobetasol propionate was greater than 3000 mg/kg.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Ulobetasol on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.